

1 **Efficacy and Safety of Acupuncture for Acute Gouty Arthritis: A**
2 **Systematic Review and Network Meta-Analysis**

3 **Author Names:**

4 Yuxiao Cai^{1†}, Yifan Liu^{2†}, Qinglong Kang¹, Shiji Zhu¹, Qianqian Wang¹, Chunmei Sun¹,
5 Yin Gu^{1*}

6 **Institution**

7 ¹ Mianyang Hospital of TCM, Chengdu University of Traditional Chinese Medicine ,
8 MianYang, China

9 ² School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine,
10 Chengdu, China

11 [†]These authors have contributed equally to this work and share first authorship.

12

13 ***Correspondence:** Yin Gu, 1137865395@qq.com

14

15 **Abstract:**

16 Acute gouty arthritis (AGA) severely affects the quality of life of patients due to its
17 persistent, recurrent, and debilitating characteristics. Acupuncture holds a pivotal role as
18 a classical alternative therapy in managing gouty arthritis. This study aimed to assess the
19 clinical effectiveness of various acupuncture methods used in conjunction with
20 conventional medications for treating acute gouty arthritis. We conducted a search of
21 seven English and Chinese databases up to February 10, 2024, and analyzed the data
22 using R software version 4.4.0. The study included a total of 37 randomized controlled
23 trials(RCT), encompassing 2,801 patients. The network meta-analysis (NMA) results are

24 as follows: Fire acupuncture demonstrated the highest effectiveness in improving cure
25 rates. Acupuncture combined with conventional medication was found to be the most
26 effective for reducing VAS scores. Additionally, Acupuncture combined with
27 conventional medication proved most effective in lowering uric acid levels. For reducing
28 ESR, the combination of blood-letting therapy and conventional drugs showed the
29 greatest efficacy. No statistically significant differences were found among the different
30 interventions regarding the reduction of TCMSS and CRP levels. In conclusion, fire
31 acupuncture showed the greatest overall effectiveness. Acupuncture with conventional
32 medication best reduced VAS scores and uric acid levels, while blood-letting therapy
33 combined with conventional drugs was most effective in lowering ESR.

34 **Keywords:** Acute gouty arthritis; Acupuncture; Randomized controlled trial; Net meta-
35 analysis

36

37

38

39

40

41

42

43

44

45

46

47 **1 Introduction**

48 Gouty arthritis (GA) is an inflammatory condition resulting from the deposition of urate
49 crystals in various tissues, including the joint capsule, bursa, cartilage, and surrounding
50 structures. It is prevalent in men and can be prevented by oral uric acid-lowering drugs,
51 along with lifestyle modifications such as weight loss and adhering to a low-purine diet,
52 to prevent gout flares. Acute gouty arthritis typically manifests with sudden onset at
53 night, characterized by severe pain in the affected joints, accompanied by redness,
54 swelling, heat, tenderness to touch, weakness, fever, headache, and other symptoms¹.
55 Currently, there is no definitive cure for gouty arthritis. The American College of
56 Rheumatology (ACR) and the European League Against Rheumatism (EULAR) advise
57 managing gouty arthritis with medications such as non-steroidal anti-inflammatory drugs
58 (NSAIDs), glucocorticoids, and colchicine. However, many side effects (e.g.,
59 gastrointestinal adverse reactions, jaundice, proteinuria, etc.) are produced by these drugs
60 in the course of treatment²⁻⁴. Acupuncture is a complementary and alternative therapy
61 rooted in the meridian theory of traditional Chinese medicine. It has been extensively
62 used for the treatment of conditions such as knee osteoarthritis, ankylosing spondylitis,
63 and various other forms of arthritis, often demonstrating encouraging clinical results⁵⁻⁷.
64 Acupuncture is commonly used in conjunction with conventional drugs for the treatment
65 of gouty arthritis. Previous studies have confirmed that acupuncture combined with
66 conventional drugs is more effective than conventional drugs alone⁵. However, various
67 types of acupuncture such as electroacupuncture, moxibustion, and fire acupuncture exist,
68 yet direct comparisons of their efficacy remain scarce. Therefore, the selection of
69 appropriate acupuncture treatments in clinical practice remains contentious. Network

70 meta-analysis (NMA) advances beyond conventional pairwise meta-analysis techniques.
71 Based on the current study, NMA enables direct and indirect comparisons of various
72 acupuncture therapies. By synthesizing and evaluating various comparisons, this
73 approach ranks the relative effectiveness of different acupuncture therapies.
74 Consequently, this study utilized NMA to assess the relative efficacy of multiple
75 acupuncture methods for treating gouty arthritis, with the goal of identifying the most
76 effective treatment strategies for clinical practice.

77 **2Materials and methods**

78 2.1 Register

79 The network meta-analysis was performed in line with the PRISMA-NMA guidelines.
80 The research has been formally registered with PROSPERO, and details can be accessed
81 via PROSPERO under registration number CRD42021278233.

82 2.2 Criteria for Inclusion and Exclusion

83 2.2.1 Study Design

84 This review incorporated randomized controlled trials (RCTs) published in both English
85 and Chinese languages.

86 2.2.2 Participant Criteria

87 Participants with acute gouty arthritis were required to meet specific diagnostic criteria,
88 such as the 2015 Gout Classification Criteria established by the American College of
89 Rheumatology and the European League Against Rheumatism, without regard to their
90 age or sex ⁸.

91 2.2.3 Treatment Protocols

92 The intervention for patients in the experimental group involved a regimen combining

93 various acupuncture therapies with standard medications. These therapies included
94 conventional acupuncture, Patients in the treatment group received a combination of
95 acupuncture-related therapies along with conventional drugs. The therapeutic approaches
96 encompassed conventional acupuncture, warming acupuncture, electroacupuncture, fire
97 acupuncture, blood-letting, moxibustion, buried acupuncture therapy, and acupoint
98 injections. In contrast, patients in the control group received treatment with either
99 conventional medications alone or combined with acupuncture-related therapies.
100 Consistency in the use of different conventional drugs, whether administered alone or in
101 combination, was maintained across both groups in the study.

102 2.2.4 Outcome Measures

103 The primary outcome measure was the cure rate, characterized by the resolution of
104 clinical symptoms and normalization of serum marker criteria. The secondary outcome
105 indicators encompassed the Visual Analogue Scale (VAS), serological markers such as
106 C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), blood uric acid (UA),
107 and adverse reactions (AEs).

108 2.2.5 Exclusion Criteria

109 (1). Lack of clear diagnosis criteria; (2). Absence of defined outcome indicators; (3)
110 Inclusion of multiple Traditional Chinese Medicine (TCM) therapies, including cupping,
111 traditional Chinese herbs, and combinations such as acupuncture with moxibustion and
112 electroacupuncture; (4). Duplicate publication of studies; (5). Incomplete data despite
113 attempts to contact the authors.

114

115 2.3 Literature Search Strategy

116 We searched PubMed, EMBASE, Web of Science, Cochrane Library, China National
117 Knowledge Infrastructure (CNKI), Wan Fang, and VIP databases for randomized
118 controlled trials (RCTs) investigating acupuncture combined with conventional drugs for
119 the treatment of acute gouty arthritis. We utilized a comprehensive set of search terms
120 including acupuncture, electroacupuncture, warm acupuncture, fire acupuncture, blood-
121 letting therapy, moxibustion, acupoint catgut embedding, acupoint injection,
122 acupuncture-knife therapy, and AGA in both Chinese and English languages. The
123 PubMed database search strategy is outlined in Table 1.

124 2.4 Literature Review and Data Extraction

125 Duplicates were removed using EndNote X9 software, followed by an initial screening of
126 each study based on its title and abstract. Subsequently, full texts were screened to
127 exclude studies not meeting the inclusion criteria. Data extraction was conducted
128 independently by two researchers (Cai and Liu) according to predefined criteria.

129 Disagreements were resolved by a third researcher (Zhu) to reach a final decision. In case
130 of any disagreement, the third researcher (Zhu) will arbitrate and make the final decision.

131 Information extraction involves capturing details such as title, authors, publication year
132 and month, diagnostic criteria used, sample sizes, details of interventions in both
133 treatment and control groups including doses, treatment procedures, and outcome
134 indicators.

135 2.5 Evaluation of the Risk of Bias

136 Two independent researchers (Cai and Liu) will assess quality using the RCT risk of bias
137 assessment tool from the Cochrane Handbook of Systematic Reviews version 2.0. Any
138 discrepancies between the two researchers will be resolved with assistance from a third

139 researcher (Zhu). Evaluation criteria included Randomization process、 Deviations from
140 intended interventions、 Missing outcome data、 Measurement of the outcome and
141 Selection of the reported result.

142 2.6 Statistical Analysis

143 R 4.4.0 was employed to create an evidence network diagram illustrating the comparative
144 relationships among interventions for each outcome indicator. Small sample effects and
145 publication bias were assessed using comparison-correction funnel plots. Simultaneously,
146 a network meta-analysis was conducted using R 4.4.0, implementing the Markov Chain
147 Monte Carlo (MCMC) consistent model within a Bayesian framework. The simulation
148 involved four chains with a total of 50,000 iterations—20,000 for annealing and 30,000
149 for sampling. The assumption of MCMC convergence was assessed using the Potential
150 Scale Reduction Factor (PSRF), while the stability and consistency of the results were
151 evaluated using the MCMC fitting model.

152 The mean difference (MD) was used for continuous data, and odds ratios were used for
153 dichotomous data, with all results reported using 95% confidence intervals (CI). To rank
154 the cumulative probability of each outcome measure for each intervention, the surface
155 under the cumulative ranking (SUCRA) was utilized. A higher SUCRA value indicated a
156 more effective treatment option.

157 **3 Results**

158 3.1 Literature Screen

159 Initially, 3,060 papers were retrieved for this study. After thorough screening and re-
160 screening, 37 randomized controlled trials (RCTs) involving 2,801 patients were
161 included^{5, 9-44}. The literature screening process proceeded as follows: (Figure1)

162 3.2 Characteristics of the Included Studies

163 Among the 37 included studies, the distribution of therapies was as follows: 7 studies^{10,}
164 ^{20, 24, 27, 32, 34, 37} reported acupuncture therapy; 6 studies^{9, 13, 31, 38, 39, 41} reported acupuncture
165 combined with conventional drugs, 2 studies^{19, 23} reported acupotomy therapy; 2
166 studies^{17, 21} reported acupotomy combined with conventional drugs; 8 studies^{12, 18, 25, 26, 29,}
167 ^{36, 40, 43, 44} reported blood-letting therapy; 3 studies^{28, 30, 36} reported electroacupuncture
168 combined with conventional drugs; 37 studies^{5, 9-44}, 3 studies^{5, 16, 33} reported
169 electroacupuncture combined with conventional drugs; 3 studies^{14, 15, 35} reported fire
170 acupuncture; 2 studies^{22, 42} reported warm acupuncture; 1 study¹¹ reported warm
171 acupuncture combined with conventional drugs. Among the included studies: 36 studies
172 ⁹⁻⁴⁴ were two-arm studies and 1 study⁵ was a three-arm study.

173 The reported outcomes were distributed as follows: Visual Analog Scale (VAS) scores:
174 Reported in 17 studies (5, 10, 11, 16, 19, 23, 27-29, 32-36, 38, 40, 41); Adverse Events
175 (AEs): Reported in 10 studies (10, 11, 16, 22, 25, 27, 28, 32, 33, 38). Cure rates: Reported
176 in 32 studies^{9-20, 22-24, 26-31, 34-44}; Traditional Chinese Medicine Symptom Scores
177 (TCMSS): Reported in seven studies^{11, 14, 31, 36, 38, 39, 42}; C-reactive protein (CRP):
178 Reported in eight studies^{11, 28, 31-33, 36, 39, 43}; Uric acid (UA): Reported in 27 studies^{9-11, 13-}
179 ^{15, 17-21, 23-25, 27-29, 31, 32, 34, 36, 38-40, 42-44}; Erythrocyte sedimentation rate (ESR): Reported in
180 nine studies^{11, 13, 25, 28, 31, 32, 36, 39, 43}; Visual Analog Scale (VAS) scores: Reported in 17
181 studies^{5, 10, 11, 16, 19, 23, 27-29, 32-36, 38, 40, 41}; Adverse Events (AEs): Reported in 10 studies^{10,}
182 ^{11, 16, 22, 25, 27, 28, 32, 33, 38}. Tables 2 and 3 outline the key characteristics of the included
183 studies and interventions, respectively.

184 3.3 Results of the Risk of Bias

185 Various methods were used to achieve random sequences and allocation concealment in
186 the reviewed studies. Specifically, 19 studies utilized randomized number tables^{9-11, 13, 14,}
187 ^{16, 25-29, 33-39, 42}, one study employed lottery randomization¹², and single studies used
188 random envelopes⁵ and interval random methods (reference 43), respectively⁴³. The
189 remaining 15 studies^{15, 17-24, 30-32, 40, 41, 44} mentioned the use of randomization without
190 specifying the method. In terms of blinding of investigators and subjects, neither blinding
191 was reported due to intervention limitations. Regarding incomplete reporting, selective
192 reporting, and other biases, all 37 studies included in the analysis provided complete data
193 without selective reporting or other biases. The results of the risk of bias assessment are
194 presented in Figure 2.

195 3.4 Directly Compared Meta-Analysis Results

196 In terms of cure rate, acupuncture therapy, acupuncture combined with conventional
197 drugs, blood-letting therapy, blood-letting therapy combined with conventional drugs,
198 and fire acupuncture demonstrated superior efficacy compared to conventional drugs.
199 There was no statistically significant difference observed between acupotomy, warm
200 acupuncture therapy, electroacupuncture combined with conventional drugs, and
201 conventional drugs. Other therapies have been studied in too few relevant studies to draw
202 meaningful comparisons with conventional drugs. No relevant comparisons between
203 different acupuncture treatments were conducted, as no cases were included where these
204 treatments were directly compared with each other.

205 Acupuncture combined with conventional drugs showed greater efficacy than
206 conventional drugs alone in reducing TCMSS scores. Other therapies have not been
207 sufficiently studied in relevant studies to provide meaningful comparisons with

208 conventional drugs.

209 In terms of reducing CRP levels, acupuncture combined with conventional drugs was
210 more effective than conventional drugs alone, while there was no statistically significant
211 difference observed between blood-letting therapy and conventional drugs. Other
212 therapies have been studied in too few relevant studies to allow for meaningful
213 comparisons with conventional drugs.

214 In terms of reducing UA levels, acupuncture therapy, acupuncture therapy combined with
215 conventional drugs, acupotomy combined with conventional drugs, blood-letting therapy,
216 blood-letting therapy combined with conventional drugs, and fire acupuncture all
217 demonstrated superior results compared to conventional drugs. And there was no
218 statistically significant difference observed between acupotomy alone and conventional
219 drugs.

220 In terms of reducing ESR (erythrocyte sedimentation rate), acupuncture combined with
221 conventional drugs, blood-letting therapy, and blood-letting therapy combined with
222 conventional drugs all showed greater efficacy compared to conventional drugs. Other
223 therapies have not been sufficiently studied in relevant research to provide meaningful
224 comparisons with conventional drugs.

225 Acupuncture, acupotomy, blood-letting therapy alone, and their combinations with
226 conventional drugs, as well as electroacupuncture in conjunction with conventional
227 medications, all showed superior efficacy in reducing VAS (Visual Analog Scale) scores
228 compared to conventional drugs alone. Other therapies have not been sufficiently studied
229 in relevant research to provide meaningful comparisons with conventional drugs.

230 3.4.7 Examination of Heterogeneity

231 Within directly comparable meta-analyses, certain outcomes demonstrated variability.
232 Examination of the original data suggested potential methodological heterogeneity in the
233 included studies, primarily due to insufficient descriptions of blinding methods and
234 allocation concealment. Additionally, clinical heterogeneity may have arisen from
235 variations in patient populations, acupoint selections, and surgical techniques. However,
236 because of insufficient detailed descriptions in the primary studies and a limited number
237 of studies for specific outcomes, conducting subgroup analyses to explore the sources of
238 heterogeneity was not possible.

239 3.5 Findings from Network Meta-Analysis

240 3.5.1 Diagram of Evidence Network

241 A total of thirty-two studies^{9-20, 22-24, 26-31, 34-44} contributed data on cure rates across 11
242 interventions, illustrating an incomplete closed-loop network. Seven studies^{11, 14, 31, 36, 38,}
243^{39, 42} reported TCMSS for 7 interventions without forming a closed loop. Eight articles^{11,}
244^{28, 31-33, 36, 39, 43} reported on CRP, involving eight intervention modalities, without
245 completing the closed loop. There were 27 articles^{9-11, 13-15, 17-21, 23-25, 27-29, 31, 32, 34, 36, 38-40,}
246⁴²⁻⁴⁴ reporting on UA involving 11 interventions that did not form a closed loop. Nine
247 articles^{11, 13, 25, 28, 31, 32, 36, 39, 43} reported on ESR involving 7 interventions without forming
248 a closed loop. There were 17 studies^{5, 10, 11, 16, 19, 23, 27-29, 32-36, 38, 40, 41} reporting on VAS
249 scores involving 9 interventions that did not form a closed loop. The width of the line
250 connecting the two interventions correlates with the number of studies that compared
251 them. The evidence network diagram for the cure rate is depicted in Figure 3.

252

253 3.5.2 Results of the cure rate

254 Thirty-two studies^{9-20, 22-24, 26-31, 34-44} reported cure rates. The results indicated that
255 acupuncture [MD = 2.74 (95% CI: 1.49, 4.92)], acupuncture combined with conventional
256 drugs [MD = 2.51 (95% CI: 1.35, 4.96)], blood-letting therapy [MD = 2.32 (95% CI:
257 1.48, 3.77)], and fire acupuncture [MD = 5.65 (95% CI: 2.31, 13.61)] demonstrated
258 superior outcomes compared to conventional drugs. Additionally, fire acupuncture [MD
259 = 4.09 (95% CI: 1.09, 14.75)] showed greater efficacy than electroacupuncture combined
260 with conventional drugs. However, therapies such as acupuncture and acupuncture
261 combined with conventional drugs did not show statistically significant differences
262 compared to conventional drugs. Overall, no particularly significant differences in
263 efficacy were observed among the various individual acupuncture treatments for the
264 disease. (Table4) The probability ranking for improving cure rates was as follows: fire
265 acupuncture > acupuncture > acupuncture combined with conventional drugs > blood-
266 letting therapy > blood-letting therapy combined with conventional drugs > warm
267 acupuncture therapy > warm acupuncture therapy combined with conventional drugs >
268 electroacupuncture combined with conventional drugs > acupotomy combined with
269 conventional drugs > acupotomy > conventional drugs.(Table5)

270 3.5.3 Results of TCMSS

271 Seven studies^{11, 14, 31, 36, 38, 39, 42} reported TCMSS. The findings indicated no statistically
272 significant difference in efficacy among the seven interventions: conventional drugs,
273 acupuncture combined with conventional drugs, blood-letting therapy combined with
274 conventional drugs, warm acupuncture therapy combined with conventional drugs,
275 electroacupuncture combined with conventional drugs, fire acupuncture, and warm
276 acupuncture therapy (Table 6). The probability ranking for reducing TCMSS was as

277 follows: warm acupuncture therapy combined with conventional drugs > blood-letting
278 therapy combined with conventional drugs > acupuncture combined with conventional
279 drugs > fire acupuncture > electroacupuncture combined with conventional drugs > warm
280 acupuncture therapy > conventional drugs (Table 7).

281 3.5.4 Results of VAS Scores

282 Seventeen studies^{5, 10, 11, 16, 19, 23, 27-29, 32-36, 38, 40, 41} reported results of the VAS score. The
283 results indicated that acupuncture combined with conventional drugs [MD = 1.75 (95%
284 CI: 0.36, 3.14)], acupotomy [MD = 1.45 (95% CI: 0.45, 2.45)], and blood-letting therapy
285 [MD = 1.17 (95% CI: 0.23, 2.11)] were more effective in reducing VAS scores compared
286 to conventional drugs. Statistically significant differences were not observed in the
287 remaining studies (Table 8). The ranking of the probability for reducing the VAS score
288 was as follows: acupuncture combined with conventional drugs > acupotomy > fire
289 acupuncture > blood-letting therapy > blood-letting therapy combined with conventional
290 drugs > electroacupuncture combined with conventional drugs > acupuncture > warm
291 acupuncture combined with conventional drugs > conventional drugs (Table 9).

292 3.5.5 Results of UA

293 A total of twenty-seven studies^{9-11, 13-15, 17-21, 23-25, 27-29, 31, 32, 34, 36, 38-40, 42-44} presented results
294 on UA. The results demonstrated that acupuncture [MD = 64.81 (95% CI: 13.75, 118.68)]
295 and acupuncture combined with conventional drugs [MD = 77.85 (95% CI: 15.3,
296 151.89)] were more effective in reducing UA compared to conventional drugs. The
297 differences observed in the remaining studies were not statistically significant (Table 10).
298 The ranking of the probability of reducing UA was as follows: acupuncture combined
299 with conventional drugs > acupotomy combined with conventional drugs > acupuncture

300 > warm acupuncture therapy > blood-letting therapy > fire acupuncture > blood-letting
301 combined with conventional drugs > acupotomy> warm acupuncture combined with
302 conventional drugs > electroacupuncture combined with conventional drugs >
303 conventional drugs(Table 11).

304 3.5.6 Results of CRP

305 Eight studies^{11, 28, 31-33, 36, 39, 43} reported CRP results. The findings suggested no
306 statistically significant differences among the interventions(Table 12). To assess the
307 likelihood of CRP reduction, the outcomes were ranked as follows: warm acupuncture
308 combined with conventional drugs > blood-letting therapy combined with conventional
309 drugs > blood-letting therapy > acupuncture combined with conventional drugs >
310 electroacupuncture combined with conventional drugs > conventional drugs >
311 acupuncture(Table 13).

312 3.5.7 Results of ESR

313 Nine studies^{11, 13, 25, 28, 31, 32, 36, 39, 43} reported results for ESR. The results showed that
314 acupuncture combined with conventional drugs [MD = 6.13 (95% CI: 0.55, 11.66)] and
315 blood-letting therapy combined with conventional drugs [MD = 9.6 (95% CI: 3.06,
316 17.92)] demonstrated better outcomes compared to conventional drugs. The differences
317 observed among the remaining interventions were not statistically significant (Table 14).
318 For ranking the probability of reducing ESR, the results were as follows: blood-letting
319 therapy combined with conventional drugs > blood-letting therapy alone > acupuncture
320 alone > acupuncture combined with conventional drugs > warm acupuncture combined
321 with conventional drugs > conventional drugs alone(Table15).

322 3.5.7 Evaluation of Small Sample Effects

323 A comparison-adjusted funnel plot depicting the cure rate for primary outcome indicators
324 was created using R version 4.4.0 software. Combined with Figure 4 and the Egger test of
325 $P > 0.05$, this suggests that potential publication bias or small-sample effects within the
326 research network are highly unlikely.

327 3.6 Adverse Reactions

328 Adverse reactions were reported in 10 studies^{10, 11, 16, 22, 25, 27, 28, 32, 33, 38} (10, 11, 16, 22, 25,
329 27, 28, 32, 33, 38)(Table 16). Overall, the adverse reactions associated with various
330 acupuncture-related therapies were generally lower than those observed in the
331 conventional drug group, and no serious adverse reactions related to acupuncture were
332 reported.

333 Table 16 Adverse reaction of the included studies.

334

335 4 Discussion

336 Acute gouty arthritis (AGA) is characterized by the deposition of monosodium urate
337 crystals within joints, initiating an inflammatory cascade that culminates in the release of
338 various inflammatory mediators into the joint cavity⁸. This process manifests clinically as
339 localized redness, swelling, warmth, and pain in the affected joints. As the most prevalent
340 inflammatory arthritis in men, gout affects 1-2 percent of adults in developed countries⁴⁵⁻
341 ⁴⁷. Gouty arthritis resulting from hyperuricemia is significantly linked to an increased risk
342 of hypertension, diabetes, renal disease, and cardiovascular disease⁴⁸. Therefore, early
343 intervention in gouty arthritis will significantly improve patient prognosis. ^{1, 49}. Currently,
344 the primary first-line therapeutic agents in clinical practice are colchicine and non-
345 steroidal anti-inflammatory drugs (NSAIDs), supplemented by a short glucocorticoid

346 therapy if needed for anti-inflammatory purposes. Research indicates that drugs like
347 colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids can
348 lead to significant side effects and may induce resistance in certain patients, thereby
349 potentially diminishing treatment efficacy⁵⁰. Acupuncture serves as a pivotal component
350 in the management of acute gouty arthritis, offering a dependable and safe alternative
351 therapy⁴⁹. Research has shown the effectiveness and safety of acupuncture when
352 combined with conventional medications^{14, 17, 21, 25}. However, current research
353 emphasizes the importance of identifying the optimal combination of therapies⁵¹.
354 This study aimed to evaluate the impact of acupuncture-related therapies combined with
355 conventional drugs on outcomes such as the cure rate, VAS (Visual Analog Scale), TCMSS
356 (Traditional Chinese Medicine Symptom Score), UA (uric acid levels), CRP (C-reactive
357 protein), and ESR (erythrocyte sedimentation rate) in patients diagnosed with acute gouty
358 arthritis (AGA). The Visual Analogue Scale (VAS) is widely employed in assessing
359 remission in gout patients by evaluating pain levels and continuously monitoring disease
360 activity. Serological biomarkers such as CRP, ESR, and UA are crucial for evaluating the
361 active stage of gout, reflecting the extent of inflammation and tissue damage in those
362 affected. The study results indicated that fire acupuncture was the most effective treatment
363 in terms of significantly increasing the cure rate. The combination of acupuncture with
364 conventional drugs demonstrated significant efficacy in reducing VAS scores. Moreover,
365 this combined approach has been identified as highly effective in reducing UA levels.
366 Blood-letting therapy combined with conventional drugs was found to be the most effective
367 in reducing ESR. However, there were no statistically significant differences observed
368 among the various interventions in terms of reducing TCMSS and CRP.

369 Based on the study findings, the highest rankings were achieved by: blood-letting
370 combined with conventional drugs, acupuncture combined with conventional drugs, and
371 fire acupuncture. Recent research indicates that acupuncture is effective in reducing pain
372 and improving the quality of life in patients with AGA. Its efficacy may be associated with
373 the modulation of inflammatory factors, serum metabolites, and neurotransmitter pathways.
374 Both blood-letting and fire acupuncture techniques have evolved from and refined
375 traditional acupuncture theory. Blood-letting therapy involves the therapeutic use of
376 acupuncture or knives to puncture or incise specific points and areas of the body,
377 facilitating the controlled release of small amounts of blood. Blood-letting therapy has been
378 shown to modulate the immune response by decreasing levels of IL-1, IL-8, and TNF- α ⁵²⁻
379 ⁵⁴, while simultaneously upregulating levels of IL-4 and IL-10^{55, 56}, and influencing the
380 TLR4/IL-1 β signaling pathway. Simultaneously, blood-letting therapy can reduce serum
381 metabolite levels of methionine, accelerate uric acid excretion, influence the L-
382 arginine/nitric oxide signaling pathway in the human body, regulate neurotransmitters, and
383 promote the alleviation of symptoms in patients with acute gouty arthritis²⁵. Fire
384 acupuncture is a therapeutic technique in which acupuncture, heated red-hot over a fire, is
385 rapidly inserted into the body to treat various diseases. Fire acupuncture can effectively
386 halt the onset and progression of acute gouty joint inflammation by inhibiting the
387 expression and activation of the NALP3 inflammasome and IL-1 β inflammatory signaling
388 pathways. Interestingly, in a rat model of acute gouty arthritis, fire acupuncture has been
389 observed to rapidly reduce serum levels of NALP3 and IL-1 β , similar to the effects of
390 colchicine. Furthermore, fire acupuncture has been shown to ameliorate pathological
391 changes in the synovial membrane of joints to a degree comparable to that of colchicine⁵⁷,

392 58.

393 Nevertheless, this study has some limitations. One major issue is that several of the
394 included studies did not clearly detail their methods for randomization, allocation
395 concealment, or blinding, potentially affecting the validity and reliability of the results.
396 Secondly, the small sample sizes in the included studies may have limited the precision
397 and generalizability of the results. Thirdly, variability existed among the included studies
398 regarding the type and dosage of conventional drugs, as well as the selection of acupuncture
399 points, depth, and duration of acupuncture-related therapies. This variability may have
400 contributed to clinical heterogeneity across the studies. Fourthly, the limited number of
401 primary studies and the omission of additional acupuncture methods such as bloodletting
402 therapy and acupoint injections prevented a comprehensive evaluation of the effectiveness
403 of all acupuncture-related interventions.

404 Overall, a comprehensive comparison of outcome metrics across the six different
405 therapies demonstrated that fire acupuncture was the most effective treatment in terms of
406 significantly increasing the cure rate. Combining acupuncture with conventional drugs
407 was found to be highly effective in reducing VAS scores and lowering UA levels.

408 Acupuncture combined with conventional drugs has shown to be the most effective
409 approach for lowering UA levels. Blood-letting therapy combined with conventional
410 drugs was found to be the most effective in reducing ESR. In clinical practice, treatments
411 should be selected based on individual circumstances and clinical presentation. Given the
412 limited number of available studies, many of which are of suboptimal quality, there is a
413 need for additional multicenter, large-scale, prospective randomized controlled trials
414 (RCTs) to confirm these results.

415

416 **AUTHOR CONTRIBUTIONS**

417 Yifan Liu conceptualized the study and wrote the manuscript.. Yuxiao Cai analyzed the
418 data and wrote the manuscript. Qinglong Kang; Shiji Zhu; Qianqian Wang and Chunmei
419 Sun collected the data. Yin Gu revised the manuscript.

420 **ADDITIONAL INFORMATION**

421 There are no declared conflicts of interest.

422 **DATA AVAILABILITY**

423 Registration of Systematic Review: This study has been registered with PROSPERO
424 under registration number CRD42021278233. Detailed information can be accessed at
425 PROSPERO.

426 **ACKNOWLEDGMENTS**

427 We thank the subjects for their committed participation in this study.

428 **FUNDING INFORMATION**

429 This study was funded by the Sichuan Province Science and Technology Support
430 Program. (2020YFS0522).

431

432

433 **Reference**


- 434 1. Richette, P.; Bardin, T. Gout, *Lancet (London, England)*. **2010**, *375*, 318-328.
- 435 2. White, W. B.; Saag, K. G.; Becker, M. A., et al. Cardiovascular Safety of Febuxostat or
436 Allopurinol in Patients with Gout, *The New England journal of medicine*. **2018**, *378*, 1200-1210.
- 437 3. Hall, C. J.; Sanderson, L. E.; Lawrence, L. M., et al. Blocking fatty acid–fueled mROS
438 production within macrophages alleviates acute gouty inflammation. **2018**, *128*, 1752-1771.
- 439 4. Schwier, N. C.; Cornelio, C. K.; Boylan, P. M. A systematic review of the drug-drug interaction
440 between statins and colchicine: Patient characteristics, etiologies, and clinical management

- 441 strategies, *Pharmacotherapy*. **2022**, **42**, 320-333.
- 442 5. Liu, L. M.; Yin, P.; Hu, J. W.; Chen, Y. L. [Immediate analgesic effect of electroacupuncture
443 combined with diclofenac sodium on acute gouty arthritis: a randomized controlled trial], *Zhongguo*
444 *zhen jiu = Chinese acupuncture & moxibustion*. **2023**, **43**, 766-770.
- 445 6. Hu, J.; Mao, Y.; Zhang, Y.; Ye, D.; Wen, C.; Xie, Z. Moxibustion for the treatment of ankylosing
446 spondylitis: a systematic review and meta-analysis, *Annals of palliative medicine*. **2020**, **9**, 709-
447 720.
- 448 7. Lee, W. B.; Woo, S. H.; Min, B. I.; Cho, S. H. Acupuncture for gouty arthritis: a concise report
449 of a systematic and meta-analysis approach, *Rheumatology (Oxford, England)*. **2013**, **52**, 1225-
450 1232.
- 451 8. Neogi, T.; Jansen, T. L.; Dalbeth, N., et al. 2015 Gout classification criteria: an American
452 College of Rheumatology/European League Against Rheumatism collaborative initiative, *Annals of*
453 *the rheumatic diseases*. **2015**, **74**, 1789-1798.
- 454 9. Ai, M.; Zhao, N.; Wang, X. B. Effect of Acupuncture on Clinical Symptoms and Serum Uric
455 Acid of Gouty Arthritis, *Journal of Clinical Acupuncture and Moxibustion*. **2012**, **28**, 23-24.
- 456 10. Chen, Z. F. Clinical Observation on Acupuncture Treatment of Acute Gout Arthritis, *Medical*
457 *Innovation of China*. **2019**, **16**, 75-78.
- 458 11. Chen, Z. Q.; Lie, B. Clinical Observation of Warm-needling Moxibustion at Mingmen Point for
459 Treatment of Refractory Gouty Arthritis Patients with Cold-damp Obstruction Syndrome, *Journal of*
460 *Guangzhou University of Traditional Chinese Medicine*. **2020**, **37**, 2365-2369.
- 461 12. Dong, H.; Gu, F. The randomized parallel controlled study of blood-letting therapy in the
462 treatment of acute gouty arthritis, *Journal of Practical Traditional Chinese Internal Medicine*. **2013**,
463 **27**, 149-150.
- 464 13. Fang, K. Observation on the efficacy of acupuncture in the treatment of acute gouty arthritis,
465 *Renowned Doctor*. **2021**, 117-119.
- 466 14. Fang, X. Y.; Li, Z. Y.; Lu, C. N.; Xie, L. Q.; Li, L. X. Clinical Observation on Midnight-noon Ebb-
467 flow Acupuncture Therapy Combined with Heat Needle in the Treatment of Acute Gouty Arthritis,
468 *Journal of Guangzhou University of Traditional Chinese Medicine*. **2022**, **39**, 350-355.
- 469 15. Fang, X. Y.; Liu, W. W.; Lu, C. N.; Xie, L. Q.; Li, L. X. Clinical Efficacy Observation of Fire
470 Needle based on Midnight-Noon Ebb-Flow Theory on Acute Gouty Arthritis, *Journal of Emergency*
471 *in Traditional Chinese Medicine* **2021**, **30**, 131-134.
- 472 16. Gao, L.; Fu, C. A.; Yuan, Y. X. Effects of Electroacupuncture on NLRP3 Inflammatory Body of
473 Gouty Arthritis with Damp Heat Accumulation Syndrome, *World Chinese Medicine*. **2019**, **14**, 3045-
474 3049+3053.
- 475 17. He, D. C.; Zhang, Y.; Ruan, X. F. Clinical Observation of Treating Intractable Gout in the Acute
476 Stage with Needlescope Combining Medicine, *Rheumatism and Arthritis*. **2017**, **6**, 28-30+44.
- 477 18. Hu, F. C.; Chen, F.; Zheng, R. J.; Jin, X. M.; Sun, B. W. CLINICAL OBSERVITON OF

- 478 PRICKING BLOOD WITH PYRONYSIS THERAPY ON ACUTE GOUT, *The Journal of Traditional*
479 *Chinese Orthopedics and Traumatology*. **2007**, 9-10+81-82.
- 480 19. Li, W. Q.; Wang, Z. M. Observation on the efficacy of acupotomy treatment for acute gouty
481 arthritis of the foot, *Chinese Community Doctors*. **2011**, **13**, 174.
- 482 20. Li, Y. F. Observation on the effect of acupuncture in the treatment of acute gouty arthritis
483 *Electronic Journal of Clinical Medical Literature*. **2018**, **5**, 59-60.
- 484 21. Liu, J. Q.; Chen, X.; Zeng, Y. Q.; Wang, X. F.; Li, X. F. Observation on the efficacy of
485 acupotomy combined with drugs in the treatment of acute gouty arthritis, *Modern Journal of*
486 *Integrated Traditional Chinese and Western Medicine*. **2014**, **23**, 2755-2757.
- 487 22. Liu, X. Warm Acupuncture and Moxibustion for the Treatment of Gouty Arthritis in 61 Cases,
488 *Chinese Acupuncture & Moxibustion*. **2000**, DOI 10.13703/j.0255-2930.2000.09.016, 25-26.
- 489 23. Luo, Q. F.; Zhang, X. W.; Huang, Z.; Ding, Y.; Zhu, L. Y. Clinical Observation of Acupotomotor
490 Regulating Spinal Nerve and Local Release in the Treatment of Acute Gouty Arthritis, *Practical*
491 *Clinical Journal of Integrated Traditional Chinese and Western Medicine*. **2020**, **20**, 3-5.
- 492 24. Ma, X. P. Acupuncture Treatment of Gouty Arthritis and Effect on Serum Uric Acid, *Chinese*
493 *Acupuncture & Moxibustion* **2002**, 151-152.
- 494 25. Qiu, F. H.; Zhang, H. Z. Effect of pricking blood therapy on acute gouty arthritis and its effect
495 on serum metabolites, *China Medical Herald*. **2018**, **15**, 135-139+181.
- 496 26. Song, Z. J. Local bloodletting therapy for the treatment of gouty arthritis in 23 cases, *Henan*
497 *Traditional Chinese Medicine*. **2013**, **33**, 235-236.
- 498 27. Sun, J. G.; Zhu, C. L.; Yu, C. C., et al. Clinical Efficacy Study on Treatment of Acute Gouty
499 Arthritis with Needle-pricking Therapy, *Journal of Chengdu University of Traditional Chinese*
500 *Medicine*. **2016**, **39**, 29-33.
- 501 28. Qin, Z. Z.; Gao, M. Y.; Wu, J. Y., et al. Clinical Observation of Pricking Blood Combined with
502 Cupping for Acute Gouty Arthritis, *Clinical Journal of Traditional Chinese Medicine*. **2016**, **28**, 542-
503 545.
- 504 29. Tang, L. G.; Liu, C. K.; Li, M.; Fu, J. Therapeutic efficacy of puncture and bloodletting
505 decompression therapy in the treatment of gouty arthritis observed, *Modern Journal of Integrated*
506 *Traditional Chinese and Western Medicine* **2014**, **23**, 1745-1746.
- 507 30. Tian, J.; Liu, B. Clinical observation on acupuncture and bloodletting in the treatment of acute
508 gouty arthritis, *Journal of Emergency in Traditional Chinese Medicine*. **2012**, **21**, 130.
- 509 31. Wang, Y. P.; Zhang, Q. C.; Wang, Z. H. Treatment of 70 cases of gouty arthritis of the foot
510 with acupuncture based on taking FiveTransport Points combined with western medicine,
511 *Traditional Chinese Medicinal Research*. **2019**, **32**, 58-61.
- 512 32. Wu, R.; Huang, X. H.; He, J.; Chen, Z. H. Qihuang Needle Therapy in Treating 36 Senile
513 Patients Suffering Acute Gouty Arthritis, *Western Journal of Traditional Chinese Medicine*. **2020**,
514 **33**, 129-131.

- 515 33. Wu, B. Q.; Tu, X. F.; Zhang, W. B.; Li, Z. Y. Electroacupuncture therapy combined with
516 loxoprofen sodium tablets in the treatment of acute gouty arthritis in 43 cases, *Traditional Chinese*
517 *Medicinal Research*. **2021**, **34**, 29-31.
- 518 34. Xi, Y. F.; Zou, T.; Ai, Z.; Liu, Y. Y.; Zhang, Q. R. Clinical Observation on Acupuncture
519 Treatment of Acute Gouty Arthritis in Terms of Clearing Heat, Eliminating Dampness and Stasis,
520 *Acupuncture Research* **2006**, 362-364.
- 521 35. Xie, L. Q.; Li, L. X.; Huang, Y. J.; Lu, C. N.; Wong, W. G. The clinical effect of fire needle with
522 "fire stagnation requiring dissipation" treating acute gouty arthritis, *China Modern Medicine*. **2018**,
523 **25**, 190-193.
- 524 36. Xu, D.; Lu, Y. Z.; Dong, X. Observations on the Efficacy of Bloodletting Therapy for Acute
525 Gouty Arthritis and Its Effect on Inflammation-related Factors, *Shanghai Journal of Acupuncture*
526 *and Moxibustion*. **2021**, **40**, 1123-1128.
- 527 37. Xu, X. L.; Yang, J.; Zhang, X. F. Clinical efficacy observation of acupuncture in the treatment
528 of acute gouty arthritis, *Journal of Clinical Acupuncture and Moxibustion*. **2011**, **27**, 17-18.
- 529 38. Yang, L. F. Clinical Study on Acupuncture Treatment of Acute Gouty Arthritis, *Journal of*
530 *Chinese and Foreign Medicine and Pharmacy Research*. **2023**, **2**, 88-90.
- 531 39. Zhang, J. J.; Huang, D. C.; Zhang, C. H. Effect of Chifeng Yingyuan Acupuncture on Gouty
532 Arthritis in Youth, *Medical Innovation of China*. **2021**, **18**, 81-84.
- 533 40. Zhou, D.; Mao, L. W.; Gao, J. Q. Pricking Blood Therapy in the Treatment of Acute Gouty
534 Arthritis of Foot for 36 Cases, *Guangming Journal of Chinese Medicine*. **2020**, **35**, 2902-2904.
- 535 41. Zhu, X. L.; Cai, W.; Shen, W. D. Efficacy of Quintuple Puncture Combined with Celecoxib in
536 the Treatment of Acute Gout, *Journal of Emergency in Traditional Chinese Medicine*. **2022**, **31**,
537 1921-1923+1954.
- 538 42. Zong, J., J.; Gao, Y. Y.; Wang, S. Y.; He, H. N.; Zheng, J. G. 40 Cases of Acute Gouty Arthritis
539 Treated by Warming Needle Moxibustion, *Journal of Sichuan Traditional Chinese Medicine*. **2011**,
540 **29**, 115-117.
- 541 43. Zuo, Z.; Huang, P. D.; Wang, X. Y.; Pu, Y. B. Observation on the efficacy of blood stabbing at
542 Ah Yes point in the treatment of gouty arthritis based on TLR4/IL-1b signaling pathway, *Shanghai*
543 *Journal of Acupuncture and Moxibustion*. **2020**, **39**, 1176-1180.
- 544 44. Zuo, Z.; Jiang, Y. W. Clinical Observations on the Short-term and Long-term Effect of Pricking
545 Bloodletting at Ashi Points in the Treatment of Acute Gout, *Shanghai Journal of Acupuncture and*
546 *Moxibustion*. **2012**, **31**, 589-590.
- 547 45. Juraschek, S. P.; Miller, E. R., 3rd; Gelber, A. C. Body mass index, obesity, and prevalent gout
548 in the United States in 1988-1994 and 2007-2010, *Arthritis care & research*. **2013**, **65**, 127-132.
- 549 46. Khanna, D.; Fitzgerald, J. D.; Khanna, P. P., et al. 2012 American College of Rheumatology
550 guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic
551 therapeutic approaches to hyperuricemia, *Arthritis care & research*. **2012**, **64**, 1431-1446.


- 552 47. Kuo, C. F.; Grainge, M. J.; Mallen, C.; Zhang, W.; Doherty, M. Rising burden of gout in the UK
553 but continuing suboptimal management: a nationwide population study, *Annals of the rheumatic*
554 *diseases*. **2015**, **74**, 661-667.
- 555 48. van Walsem, A.; Pandhi, S.; Nixon, R. M.; Guyot, P.; Karabis, A.; Moore, R. A. Relative benefit-
556 risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and
557 cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-
558 analysis, *Arthritis research & therapy*. **2015**, **17**, 66.
- 559 49. Association, C. R. 2016 China Gout Diagnosis and Treatment Guidelines, *Chinese Journal of*
560 *Internal Medicine*. **2016**, **55**, 892-899.
- 561 50. Cronstein, B. N.; Sunkureddi, P. Mechanistic aspects of inflammation and clinical management
562 of inflammation in acute gouty arthritis, *Journal of clinical rheumatology : practical reports on*
563 *rheumatic & musculoskeletal diseases*. **2013**, **19**, 19-29.
- 564 51. Xu, D.; Zhu, X. X.; Zou, H. J.; Lin, H.; Zhao, Y. Recommendations for the diagnosis and
565 treatment of gout in China, *Chinese Journal of Internal Medicine*. **2023**, **62**, 1068-1076.
- 566 52. Chen, X. H.; Wang, H. F.; Li, H. J. Effects of different acupuncture treatments on inflammatory
567 factors in rats with acute gouty arthritis model *Chinese Journal of Gerontology*. **2019**, **39**, 403-406.
- 568 53. Liang, S.; Xia, Y. B.; Cheng, J.; Mu, Y. Y.; Lu, K. L. Experimental study on the effect of blood-
569 Letting therapy on local anti-inflammatory factors in the joints of acute gouty arthritis, *Jiangsu*
570 *Journal of Traditional Chinese Medicine*. **2017**, **49**, 80-82.
- 571 54. Wang, D.; Huang, C. Z. Analysis of clinical value of pricking blood and cupping therapy in the
572 treatment of damp-heat internal knot type of acute gouty arthritis *Journal of Community Medicine*.
573 **2020**, **18**, 445-449.
- 574 55. Ye, Q.; Sun, S. M.; Zhang, Z. Z., et al. Influence of triple-pronged acupuncture puncture of
575 blood on the level of inflammatory factors and clinical efficacy in patients with chronic gout, *Practical*
576 *Clinical Journal of Integrated Traditional Chinese and Western Medicine*. **2018**, **18**, 142-144.
- 577 56. Lv, K. L.; Xia, Y. B.; Cheng, J.; Mu, Y. Y.; Liang, S.; Luo, X. The Effects of Pricking Blood
578 Therapy on Promotor Methylation of IL-1 β , IL-10 in Rats Local Ankle Joint with Acute Gouty Ar-
579 thritis Model, *Journal of Nanjing University of Traditional Chinese Medicine*. **2017**, **33**, 509-514.
- 580 57. Lin, Y. Y.; Su, S. Y.; Qin, M. X.; Jiang, X. Y. Research Progress on Mechanism of Acupuncture
581 and Moxibustion Treating Acute Gouty Arthritis, *Liaoning Journal of Traditional Chinese Medicine*.
582 **2021**, **48**, 199-202.
- 583 58. Lu, C. N.; Xie, L. Q.; Li, L. X.; Chen, C. Y.; Huang, Y. J. Effects of fire needle on expressions
584 of NALP3 inflammasome and IL-1 β in rats with acute gouty arthritis, *Shanghai Journal of*
585 *Traditional Chinese Medicine*. **2018**, **52**, 81-86.
- 586



medRxiv preprint doi: <https://doi.org/10.1101/2024.09.21.24314132>; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


Figure 1 Flow diagram outlining the guideline selection process



medRxiv preprint doi: <https://doi.org/10.1101/2024.09.21.24314132>; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


Figure 2 Results of the risk of bias evaluation.



medRxiv preprint doi: <https://doi.org/10.1101/2024.09.21.24314132>; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

FIGURE 3. Evidence network diagram of the cure rate of differ



medRxiv preprint doi: <https://doi.org/10.1101/2024.09.21.24314132>; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

FIGURE 4. Comparison-correction funnel plot of the cure rate

1 **Table legends**

2 **TABLE 1. PubMed database retrieval strategy.**

NUMBER	SEARCH TERMS
#1	Gouty Arthritis[MESH]
#2	Gouty Arthritis[Title/Abstract]
#3	Gouty Arthritis[Title/Abstract]
#4	gout*[Title/Abstract]
#5	Acupuncture[MESH]
#6	Acupuncture[Title/Abstract]
#7	Ear Acupuncture[MESH]
#8	Ear Acupuncture[Title/Abstract]
#9	electro-acupuncture[Title/Abstract]
#10	electroacupuncture[Title/Abstract]
#11	Moxabustion[Title/Abstract]
#12	warm acupuncture[Title/Abstract]
#13	fire acupuncture[Title/Abstract]
#14	blood-letting therapy[Title/Abstract]
#15	Acupotomy[Title/Abstract]
#16	acupoint catgut embedding[Title/Abstract]
#17	acupoint injection[Title/Abstract]
#18	#1 OR #2 OR #3 OR #4
#19	#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
#20	#18 AND #19

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.24.24311103>; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

3 **Table 2 Characteristics of the included studies.**(①Cure Rate; ②TCMSS; ③CRP;
4 ④UA; ⑤VAS; ⑥ESR; ⑦Adverse)

INCLUDED STUDIES	DIAGNOSTIC CRITERIA	SAMPLE (T/C)	AGE (YEARS)	GENDER (MALE/FE MALE)	COURSE	OUTCOME INDICATORS
AIMIN20 12 ⁵⁹	ACR	25/25	C:42.05 T:41.32	C:4/21 T:3/22	/	①④
CHENZH ENFENG 2019 ⁶⁰	ACR	46/46	C : 49.7±12.8 T : 48.6±13.1	C : 41/5 T : 42/4	/	①④⑤⑦
CHENZI QING202 0 ⁶¹	ACR	55/55	C:46.1±2.9 T:42.2±3.1	C:45/10 T:41/14	C:58.2mth T:52.5mth	①②③④ ⑤⑥⑦
DONGHA N2013 ⁶²	ACR	40/40	C:49.2±16.0 T:47.8±19.5	C:23/17 T:31/9	C:10.6±8.7yr T:10.5±9.2yr	①
FANGKA I2021 ⁶³	ACR	37/37	C:48.35±9.81 T:47.46±9.56	C:24/13 T:25/12	C:6.14±2.67yr T:5.70±2.58yr	①④⑥
FANGXI AOYI202 1 ⁶⁴	ACR	30/30	C:59.07±5.91 T:58.77±7.31	C:24/6 T:22/8	C:1 ~ 8yr T:2 ~ 10yr	①④
FANGXI AOYI202 2 ⁶⁵	ACR	40/40	C:59.12±5.96 T:58.18±7.50	C:21/19 T:32/8	C:4.73±2.66yr T:4.63±2.37yr	①②④
GAOLI20 19 ⁶⁶	ACR	43/43	C:51.31±9.27 T:50.93±9.31	C:41/2 T:40/3	C:1.71±0.56yr T:1.65±0.61yr	①⑤⑦
HEDONG CHU2017 6 ⁷	ACR	30/32	C : 50.97±12. 80 T : 50.41±12.	C : 0/30 T : 0/32	C : 8.00±6.26y r T : 7.81±5.88y	①④

HUFENG CUN2007 ⁶⁸	ACR	40/40	78 C : 56.4±8.7 T : 56±9.1	C : 40/0 T : 40/0	r C : 5.9±4.6yr T : 5.7±4.4yr	①④
LIRUIFANG2018 ⁶⁹	ACR	30/30	C:40.2±4.32 T:40.4±4.11	C:13/17 T:14/16	/	①④
LIUJIQIN2014 ⁷⁰	ACR	28/36	C : 43.28±7.3 6 T : 42.75±6.4	C : 26/2 T : 33/3	C : 12.26±4.48 mth T : 11.89±4.36 mth	④
LIULUMIN2022 ⁷¹	ACR	28/29/ 30	C1:54±11 C2:55±12 T:56±12	/	/	⑤
LIUXIN2000 ⁷²	ACR	28/31	C:55±11 T:57	70/23	3-5yr	①
LIWEIQING2011 ⁷³	ACR	40/40	C : 27 ~ 60 T : 46.2±8.3	C : 40/0 T : 40/0	C : 2mth ~ 11y r T : 5.74±0.44y r	①④⑤
LUOQINFENG2020 ⁷⁴	ACR	30/30	C : 58±14 T : 59±9	C : 29/1 T : 27/3	/	①④⑤
MAXIAOPING2002 ⁷⁵	ACR	30/48	C : 43 T : 41.5	C : 26/4 T : 42/6	/	①④
QINZHIZHOU2016 ⁷⁶	ACR	35/35	C:40.09±14.6 9 T:43.71±15.7 6	70(male)	C:21.52±32.81 T:25.66±29.39	①③④⑤ ⑥⑦
QIUFANGHUI2018 ⁷⁷	ACR	20/20	C:47.33±9.46 T:46.70±8.69	C:19/1 T:18/2	C:2.30±1.32d T:1.73±0.91d	④⑥⑦
SONGJINJIE2011 ⁷⁸	ACR	20/20	C:30-70 T:34-74	C:14/6 T:13/7	C:5-13d T:4-11d	①②④
SONGZHENJIE2013 ⁷⁹	ACR	21/23	C : 22.8±4.0 T : 21.4±6.1	C : 15/6 T : 13/10	/	①
SUNJUNGANG2016 ⁸⁰	ACR	34/35	C : 45.43±10.06 T : 44.12±11.37	C : 30/4 T : 30/5	/	①④⑤⑦
TANGLIUGANG2014 ⁸¹	ACR	72/72	C:50±23.46 T:51±22.53	C:35/37 T:40/32	C:5±3.2yr T:4±3.1yr	①④⑤
TIANJING2012 ⁸²	ACR	30/30	C:50.56±12.10 T:51.30±14.22	C:23/7 T:24/6	/	①
WANGYANPING2	ACR	70/70	C:56.60±6.71 T:57.14±6.32	C:47/23 T:45/25	C:6.76±2.62yr T:6.47±2.71yr	①②③④ ⑥

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.21.24314132>; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

019 ⁸³							
WUBAIQ IANG202 1 ⁸⁴	ACR	43/43	C : 52.70±6.1 0 T : 51.28±5.6 2	C : 31/12 T : 30/13	/		①⑤⑦
WURON G2020 ⁸⁵	ACR	36/36	C : 69.33±4.8 9 T : 68.78±5.2 1	C : 26/10 T : 24/12	C : 6.74±1.92y r T : 6.44±2.43y r		①④⑤⑥ ⑦
XIELIQI NG2018 ⁸⁶	EULAR	30/30	C : 54.6±10.8 T : 50.8±9.3	C : 19/11 T : 21/9	/		①⑤
XUJIE NG2006 ⁸⁷	ACR	66/64	C : 45.1±6.1 T : 50.1±5.2	C : 53/11 T : 51/15	C : 6.2±3.1yr T : 5.6±3.7yr		①④⑤
XUDAN2 021 ⁸⁸	ACR/ EUL AR	53/53	C : 46±5 T : 46±6	C : 45/8 T : 43/10	C : 5.46±1.38y r T : 5.37±1.42y r		①②③④ ⑤⑥
XUXILIN 2011 ⁸⁹	ACR	30/30	C:44 T:42.5	C:27/3 T:28/2	/		①
YANGLI FAN2023 ⁹⁰	ACR/ EUL AR	30/30	C:46±8 T:48±10	C:22/8 T:24/6	/		①②④⑤ ⑦
ZHANGJI AOJIAO2 021 ⁹¹	ACR	20/20	C:26.0±1.4 T:26.5±1.5	C:13/7 T:14/6	C:0.52±0.28mt h T:0.54±0.25mt h		①②③④ ⑥
ZHOUDA N2020 ⁹²	ACR	34/36	C:40±12.5 T:42.5±10.6	C:26/8 T:26/10	C:4.0±1.5d T:3.5±1.7d		①④⑤
ZHUXIA OLIANG2 022 ⁹³	ACR/ EUL AR	36/36	C:43.56±8.12 T:41.31±6.84	C:36/0 T:36/0	/		①⑤
ZUOZHE NG2012 ⁹⁴	ACR	45/45	C:30 ~ 64 T:30 ~ 62	C:38/7 T:40/5	C:1mth-14yr T:1mh-15yr		①④
ZUOZHE NG2020 ⁹⁵	ACR	40/40	C : 27±2 T : 28±2	C : 36/4 T : 33/7	C : 2.0±1yr T : 1.9±1.7yr		①③④⑥

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.21.24314132>; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

5 **Table 3 Characteristics of interventions of included studies.**

Included studies	Design	Interventions(C/T)	Treatment course
AiMin2012	Two-arm	C:Colchicine 0.5mg Tid; Acupuncture(SP6,LI11,SJ5,GB20,ST44,LR3,ST36,SP10,DU14,Ashi); T:Acupuncture(SP6,LI11,SJ5,GB20,ST44,LR3,ST36,SP10,DU14,Ashi).	14d
ChenZhenfeng2019	Two-arm	C:Indomethacin 75mg bid; T: Acupuncture (ST36,SP6,SP9,LI11,Ashi).	10d
ChenZiqing2020	Two-arm	C:Celecoxib 0.2g qd, Etoricoxib 1g bid; T:Celecoxib 0.2g qd, Etoricoxib 1g bid; Warm-acupunctu	14d

		re(DU4).	
DongHan 2013	Two-arm	C:Indomethacin 25mg Tid; T:Blood-letting(LR3,SP3,EX_LE4,ST35,SP10,SP6,GB40).	10d
FangKai2 021	Two-arm	C:Colchicine(initial dose 1mg , 1h 0.5mg , 12h 0.5mg maintenance dose 0.5mg qd); Febuxostat 40mg qd; T: Acupuncture(ST44,ST36,ST40,SP9,LR3,GB40,GB41, K17,Ashi) , Colchicine(initial dose 1mg , 1h 0.5mg , 12 h 0.5mg maintenance dose 0.5mg qd); Febuxostat 40mg qd.	14d
FangXiao yi2021	Two-arm	C:Etoricoxib 120mg qd, Colchicine 0.5mg bid; T:Fire acupuncture(midnight-noon and ebb-flow doctrine).	7d
FangXiao yi2022	Two-arm	C:Etoricoxib 120mg qd, Colchicine 0.5mg bid; T:Fire acupuncture(the Naja of midnight-noon and ebb-flow doctrine).	7d
GaoLi201 9	Two-arm	C:Meloxicam 7.5mg bid, Colchicine(initial dose 1.2mg 1 h 0.6mg maintenance dose 0.6mg qd), Methylprednisolone sodium succinate qd; T: :Meloxicam 7.5mg bid, Colchicine(initial dose 1.2mg 1h 0.6mg maintenance dose 0.6mg qd), Methylprednisolone sodium succinate qd; Electroacupuncture(ST36,SP6, ST40,Ashi).	14d
HeDongch u2017	Two-arm	C : Colchicine(initial dose 1mg 1h 0.5mg maintenance dose 0.5mg), Etoricoxib 0.5mg Tid, Celecoxib 0.2g bid; Allopurinol 0.1g Tid; T : Colchicine(initial dose 1mg 1h 0.5mg maintenance dose 0.5mg), Etoricoxib 0.5mg Tid, Celecoxib 0.2g bid; Allopurinol 0.1g Tid; ;Acupotomy(Ashi).	14d
HuFengcu n2007	Two-arm	C : Indomethacin 0.25g Tid, Allopurinol 0.2g bid; T : Blood-letting(Ashi).	14d
LiRuifang 2018	Two-arm	C:Indomethacin 75mg bid; T:Acupuncture(LI11,ST36,DU14,BL23,BL28,SP9,Ashi)	10d
LiuJiqin20 14	Two-arm	C:Meloxicam15mg qd, Colchicine 0.5mg q1h; T:Acupotomy(Ashi).	20d
LiuLumin 2022	Three-arm	C1:Diclofenac 50mg qd; C2Diclofenac 100mg qd; T:Electroacupuncture(Ashi,SP2,LR3,SP3,ST44,SP6,ST36,SP9), Diclofenac 50mg qd.	6h
LiuXin20 00	Two-arm	C:Colchicine(initial dose 1.0mg□0.5mg q1h,maintenance dose 0.5mg bid); T:Warm-acupuncture(ST36,SP4,SP6,SP9,EX_LE10).	7d
LiWeiqing 2011	Two-arm	C:Diclofenac 50mg bid, Allopurinol 0.2g tid; T:Acupotomy(Ashi).	14d
LuoQinfe ng2020	Two-arm	C:Colchicine(initial dose 0.5mg q2h , maintenance dose 0.5mg tid); T:Acupotomy(Ashi).	/
MaXiaopi ng2002	Two-arm	C:Indomethacin 25mg tid, Allopurinol 100mg bid; T:Acupuncture(LI11,SP10,SP6,K13).	30d
QinZhizho	Two-arm	C:Colchicine0.5mg tid; Etoricoxib 1g tid;	10d

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.21.24314132>; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

u2016		T:Blood-letting(Ashi), Etoricoxib 1g tid.	
QiuFanghui2018	Two-arm	C:Meloxicam 7.5mg qd Colchicine(initial dose 1.0mg 0.5mg q2h, maintenance dose 0.5mg tid); T:Blood-letting(Ashi).	7d
SongJinjie2011	Two-arm	C:Indomethacin 25mg bid, Allopurinol 100mg bid; T:Warm-acupuncture(LI11,LI14,ST34,SP9,ST36,SP6,K13,Ashi).	6d
SongZhenjie2013	Two-arm	C : Ibuprofen 0.3g bid; T : Blood-letting(Ashi).	7d
SunJungang2016	Two-arm	C : Colchicine 0.5mg tid; T : Blood-letting(Ashi).	3d
TangLiugang2014	Two-arm	C:Colchicine(initial dose 1.2mg 1h 0.6mg,maintenance dose 0.6mg bid), Indomethacin 25mg tid; T:Blood-letting(Ashi).	14d
TianJing2012	Two-arm	C:Diclofenac 25mg bid, Etoricoxib 1.0g tid; T:Blood-letting(LR3,SP3,LR2,SP6,EX_LE4,ST35,SP9,SP10,ST36,ST40,GB34),Diclofenac 25mg bid,Etoricoxib 1.0g tid.	10d
WangYanping2019	Two-arm	C:Meloxicam 7.5mg bid,Etoricoxib0.5g tid; T:Acupuncture(ST36,SP6,SP9,LR3,Ashi),Meloxicam 7.5mg bid, Etoricoxib0.5g tid.	14d
WuBaiqiang2021	Two-arm	C : loxoprofen 60mg tid; T:Electroacupuncture(ST36,SP9,LR3,SP6,Ashi), loxoprofen 60mg tid;.	7d
WuRong2020	Two-arm	C : Etoricoxib 120mg qd; T : Acupuncture(SP3,GB33,GB40,LI11).	3d
XieLiqing2018	Two-arm	C : Etoricoxib 120mg qd, Colchicine 1mg qd; T : Fire acupuncture(Ashi).	7d
XiYufeng2006	Two-arm	C : Meloxicam 7.5mg qd; T : Acupuncture(EX_LE10,SP6,SP9,SP10,ST37,ST39,LI11,LI14).	20d
XuDan2021	Two-arm	C : Colchicine (initial dose 0.5mg q1h, maintenance dose 0.5mg tid); T:Blood-letting(Ashi, SP10),Colchicine(initial dose 0.5mg q1h, maintenance dose 0.5mg tid).	14d
XuXilin2011	Two-arm	C: Indomethacin 75mg bid. T:Acupuncture(ST36,SP9,K19,SJ6,ST44,ST43,SP6,Ashi).	10d
YangLifan2023	Two-arm	C:Colchicine(initial dose 1mg , 0.5mg q1h maintenance dose 0.5mg qd); T:Electroacupuncture(Ashi,SP2,LR3,SP3,ST44,SP6,ST36,SP9), Colchicine(initial dose 1mg , 0.5mg q1h maintenance dose 0.5mg qd);	7d
ZhangJiaojiao2021	Two-arm	C: Colchicine(first day 3mg , then 0.5g tid). T:Acupuncture(ST36,SP9,SP6),Colchicine initial dose 3	7d

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.21.24314132>; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

ZhouDan2020	Two-arm	C:Indomethacin 25mg tid, Allopurinol 10mg bid; 15d T: Blood-letting(Ashi).
ZhuXiaoliang2022	Two-arm	C:Celecoxib 200mg bid; 7d T:Acupuncture(Ashi,K13,SP6,ST36,SP9),Celecoxib 200mg bid.
ZuoZheng2012	Two-arm	C:Diclofenac 50mg bid , After pain control Benzbromarone 50mg qd. T: Blood-letting(Ashi).
ZuoZheng2020	Two-arm	C : Diclofenac 50mg bid , After pain control Benzbromarone 50mg qd; T : Blood-letting(Ashi);

6 Table4. NMA results of the cure rate. (1 Conventional drugs; 2 Acupuncture; 3 Acupuncture +

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.21.24314132>; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This made available under a CC-BY 4.0 International license.

7 conventional drugs; 4 Acupuncture + conventional drugs; 5 Acupuncture + conventional drugs; 6 Blood-letting; 7 Blood-letting therapy + conventional drugs; 8 Electroacupuncture + conventional drugs; 9 Warm acupuncture + conventional drugs; 10 Fire acupuncture; 11 Warm acupuncture.)

	X1	X2	X3	X4	X5	X6	X7	X8	X9	X10	X11
1	1	2.74 (1.49, 4.92)	2.51 (1.35, 4.96)	1.29 (0.39, 4.87)	1.29 (0.34, 5.07)	2.32 (1.48, 3.77)	2.06 (0.96, 4.48)	1.39 (0.53, 3.61)	1.39 (0.42, 4.65)	5.65 (2.31, 13.61)	1.96 (0.75, 5.68)
2	0.37 (0.2, 0.67)	2	0.92 (0.39, 2.32)	0.47 (0.13, 2.08)	0.47 (0.11, 2.12)	0.85 (0.41, 1.87)	0.75 (0.29, 2.03)	0.51 (0.17, 1.58)	0.51 (0.13, 1.98)	2.07 (0.71, 9.99)	0.72 (0.23, 2.46)
3	0.4 (0.2, 0.74)	1.09 (0.43, 2.55)	3	0.51 (0.13, 2.21)	0.52 (0.11, 2.28)	0.92 (0.41, 2.03)	0.82 (0.29, 2.21)	0.55 (0.17, 1.71)	0.55 (0.14, 2.14)	2.25 (0.72, 6.67)	0.78 (0.24, 2.66)
4	0.78 (0.21, 2.53)	2.12 (0.48, 7.93)	1.95 (0.45, 7.52)	4	1 (0.15, 5.98)	1.8 (0.44, 6.47)	1.6 (0.34, 6.54)	1.07 (0.21, 4.87)	1.08 (0.18, 5.7)	4.36 (0.87, 8.71)	1.52 (0.37, 3.6)
5	0.77 (0.2, 0.91)	2.12 (0.47, 8.96)	1.94 (0.44, 8.74)	1 (0.17, 6.68)	5	1.79 (0.43, 7.39)	1.6 (0.33, 7.4)	1.07 (0.2, 4.9)	1.07 (0.17, 6.47)	4.37 (0.83, 1.25)	1.53 (0.29, 8.42)
6	0.43 (0.27, 0.68)	1.18 (0.53, 2.45)	1.08 (0.49, 2.42)	0.56 (0.15, 2.27)	0.56 (0.14, 2.31)	6	0.89 (0.36, 2.16)	0.6 (0.2, 0.7)	0.6 (0.16, 2.16)	2.44 (0.87, 9.5)	0.84 (0.29, 2.65)
7	0.49 (0.22, 1.05)	1.33 (0.49, 3.47)	1.22 (0.45, 3.41)	0.63 (0.15, 2.96)	0.63 (0.14, 2.99)	1.13 (0.46, 2.81)	7	0.68 (0.19, 2.29)	0.68 (0.16, 2.82)	2.75 (0.83, 6.8)	0.95 (0.28, 3.52)
8	0.72 (0.28, 1.87)	1.97 (0.63, 6.04)	1.81 (0.58, 5.9)	0.93 (0.21, 4.85)	0.93 (0.18, 4.98)	1.67 (0.59, 4.92)	1.48 (0.44, 5.13)	8	1 (0.22, 4.72)	4.09 (1.09, 4.75)	1.41 (0.37, 5.96)
9	0.72 (0.22, 2.4)	1.97 (0.51, 7.44)	1.8 (0.47, 7.29)	0.93 (0.18, 5.64)	0.93 (0.15, 5.77)	1.66 (0.46, 6.18)	1.48 (0.35, 6.2)	1 (0.21, 4.57)	9	4.05 (0.89, 7.72)	1.41 (0.37, 3.1)
10	0.18 (0.07, 0.43)	0.48 (0.17, 1.41)	0.44 (0.15, 1.39)	0.23 (0.05, 1.15)	0.23 (0.05, 1.2)	0.41 (0.15, 1.15)	0.36 (0.12, 1.21)	0.24 (0.07, 0.91)	0.25 (0.06, 1.12)	10	0.35 (0.1, 0.41)

11	0.51 (0.18, 1.34)	1.39 (0.41, 4.29)	1.28 (0.38, 4.17)	0.66 (0.14, 3.34)	0.66 (0.12, 3.48)	1.18 (0.38, 3.46)	1.05 (0.28, 3.59)	0.71 (0.17, 2.72)	0.71 (0.14, 3.29)	2.88 (0.71,1 0.43)	11
----	-------------------------	-------------------------	-------------------------	-------------------------	-------------------------	-------------------------	-------------------------	-------------------------	-------------------------	--------------------------	----

10 **Table5. Probability ranking results of the cure rate.**(1 Conventional drugs; 2 Acupuncture;
11 3 Acupuncture + conventional drugs; 4 Acupotomy; 5 Acupotomy + conventional drugs; 6 Blood-
12 letting; 7 Blood-letting therapy + conventional drugs; 8 Electroacupuncture + conventional drugs; 9
13 Warm acupuncture + conventional drugs; 10 Fire acupuncture; 11 Warm acupuncture.)

	V1	V2	V3	V4	V5	V6	V7	V8	V9	V10	V11
1	0.000	0.000	0.000	0.000	0.000	0.001	0.017	0.097	0.284	0.392	0.209
9	0.019	0.050	0.048	0.053	0.063	0.085	0.118	0.140	0.131	0.127	0.167
10	0.778	0.119	0.046	0.053	0.048	0.040	0.005	0.000	0.001	0.000	0.000
11	0.040	0.106	0.098	0.098	0.107	0.128	0.135	0.120	0.082	0.050	0.035
2	0.045	0.252	0.221	0.172	0.128	0.088	0.054	0.027	0.010	0.003	0.000
3	0.038	0.174	0.188	0.176	0.152	0.121	0.081	0.047	0.019	0.004	0.001
4	0.021	0.050	0.043	0.047	0.056	0.072	0.101	0.128	0.127	0.135	0.220
5	0.024	0.053	0.046	0.048	0.055	0.072	0.098	0.121	0.118	0.129	0.235
6	0.010	0.082	0.159	0.209	0.218	0.165	0.099	0.043	0.013	0.002	0.000
7	0.020	0.089	0.113	0.125	0.143	0.159	0.149	0.107	0.058	0.026	0.010
8	0.007	0.026	0.037	0.047	0.062	0.098	0.143	0.168	0.157	0.131	0.123

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.21.24314132>; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

14 **Table6. NMA results of the TCMSS.** (1 Conventional drugs; 2 Acupuncture + conventional
15 drugs; 3 Blood-letting + conventional drugs; 4 Warm acupuncture+ conventional drugs; 5 Fire
16 acupuncture; 6 Warm acupuncture; 7 Electroacupuncture + conventional drugs.)

	X1	X2	X3	X4	X5	X6	X7
1	1	-2.47 (-5.62,0.75)	-2.67 (-7.2,1.88)	-3.99 (-8.52,0.52)	-1.55 (-6.04,2.93)	-0.78 (-5.85,4.27)	-1.16 (-5.65,3.36)
2	2.47 (-0.75,5.62)	2	-0.2 (-5.79,5.33)	-1.52 (-7.07,3.95)	0.92 (-4.62,6.36)	1.68 (-4.32,7.62)	1.32 (-4.25,6.78)
3	2.67 (-1.88,7.2)	0.2 (-5.33,5.79)	3	-1.33 (-7.73,5.08)	1.12 (-5.29,7.49)	1.89 (-4.92,8.67)	1.51 (-4.88,7.9)
4	3.99 (-0.52,8.52)	1.52 (-3.95,7.07)	1.33 (-5.08,7.73)	4	2.45 (-3.9,8.81)	3.21 (-3.6,9.97)	2.84 (-3.57,9.21)
5	1.55 (-2.93,6.04)	-0.92 (-6.36,4.62)	-1.12 (-7.49,5.29)	-2.45 (-8.81,3.9)	5	0.76 (-6,7.54)	0.39 (-5.95,6.76)
6	0.78 (-4.27,5.85)	-1.68 (-7.62,4.32)	-1.89 (-8.67,4.92)	-3.21 (-9.97,3.6)	-0.76 (-7.54,6)	6	-0.38 (-7.15,6.37)
7	1.16 (-3.36,5.65)	-1.32 (-6.78,4.25)	-1.51 (-7.9,4.88)	-2.84 (-9.21,3.57)	-0.39 (-6.76,5.95)	0.38 (-6.37,7.15)	7

17 **Table7. Probability ranking results of the TCMSS.** (1 Conventional drugs; 2 Acupuncture
18 + conventional drugs; 3 Blood-letting + conventional drugs; 4 Warm acupuncture+ conventional
19 drugs; 5 Fire acupuncture; 6 Warm acupuncture; 7 Electroacupuncture + conventional drugs.)

	V1	V2	V3	V4	V5	V6	V7
1	0.000	0.001	0.010	0.051	0.166	0.376	0.396

2	0.086	0.256	0.307	0.190	0.098	0.043	0.020
3	0.170	0.282	0.219	0.143	0.089	0.055	0.042
4	0.579	0.189	0.101	0.061	0.035	0.021	0.015
5	0.063	0.107	0.149	0.238	0.210	0.132	0.101
6	0.057	0.087	0.103	0.134	0.153	0.180	0.286
7	0.045	0.078	0.111	0.182	0.249	0.194	0.140

20 **Table8. NMA results of the VAS score.** (1 Conventional drugs; 2 Acupuncture; 3 Acupuncture
21 + conventional drugs; 4 Acupotomy; 5 Blood-letting; 6 Blood-letting + conventional drugs; 7
22 Electroacupuncture + conventional drugs; 8 Warm acupuncture + conventional drugs; 9 Fire
23 acupuncture.)

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.21.24314132>; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

	X1	X2	X3	X4	X5	X6	X7	X8	X9
1	1	-0.56 (-1.24,0.17)	-1.75 (-3.14,-0.36)	-1.45 (-2.45,-0.45)	-1.17 (-2.11,-0.23)	-0.83 (-1.82,0.11)	-0.69 (-1.35,0.01)	-0.47 (-1.74,0.81)	-1.44 (-3.11,0.22)
2	0.56 (-0.17,1.24)	2	-1.19 (-2.77,0.36)	-0.89 (-2.14,0.31)	-0.62 (-1.81,0.54)	-0.27 (-1.51,0.87)	-0.14 (-1.11,0.85)	0.09 (-1.4,1.53)	-0.89 (-2.71,0.9)
3	1.75 (0.36,3.14)	1.19 (-0.36,2.77)	3	0.3 (-1.41,2.01)	0.58 (-1.1,2.26)	0.92 (-0.8,2.58)	1.06 (-0.47,2.63)	1.28 (-0.6,3.17)	0.31 (-1.87,2.48)
4	1.45 (0.45,2.45)	0.89 (-0.31,2.14)	-0.3 (-2.01,1.41)	4	0.28 (-1.1,1.65)	0.62 (-0.8,1.98)	0.76 (-0.43,1.99)	0.98 (-0.65,2.6)	0 (-1.93,1.95)
5	1.17 (0.23,2.11)	0.62 (-0.54,1.81)	-0.58 (-2.26,1.1)	-0.28 (-1.65,1.1)	5	0.35 (-1.04,1.66)	0.48 (-0.66,1.67)	0.71 (-0.89,2.28)	-0.27 (-2.19,1.64)
6	0.83 (-0.11,1.82)	0.27 (-0.87,1.51)	-0.92 (-2.58,0.8)	-0.62 (-1.98,0.8)	-0.35 (-1.66,1.04)	6	0.14 (-0.99,1.36)	0.36 (-1.21,1.98)	-0.61 (-2.52,1.32)
7	0.69 (-0.01,1.35)	0.14 (-0.85,1.11)	-1.06 (-2.63,0.47)	-0.76 (-1.99,0.43)	-0.48 (-1.67,0.66)	-0.14 (-1.36,0.99)	7	0.23 (-1.24,1.65)	-0.75 (-2.57,1.03)
8	0.47 (-0.81,1.74)	-0.09 (-1.53,1.4)	-1.28 (-3.17,0.6)	-0.98 (-2.6,0.65)	-0.71 (-2.28,0.89)	-0.36 (-1.98,1.21)	-0.23 (-1.65,1.24)	8	-0.98 (-3.07,1.12)
9	1.44 (-0.22,3.11)	0.89 (-0.9,2.71)	-0.31 (-2.48,1.87)	0 (-1.95,1.93)	0.27 (-1.64,2.19)	0.61 (-1.32,2.52)	0.75 (-1.03,2.57)	0.98 (-1.12,3.07)	9

24 **Table9. Probability ranking results of the VAS score.** (1 Conventional drugs; 2
25 Acupuncture; 3 Acupuncture + conventional drugs; 4 Acupotomy; 5 Blood-letting; 6 Blood-letting +
26 conventional drugs; 7 Electroacupuncture + conventional drugs; 8 Warm acupuncture + conventional
27 drugs; 9 Fire acupuncture.)

	V1	V2	V3	V4	V5	V6	V7	V8	V9
1	0.000	0.000	0.000	0.000	0.001	0.008	0.049	0.263	0.679
2	0.001	0.008	0.028	0.069	0.139	0.220	0.286	0.208	0.040
3	0.438	0.240	0.136	0.078	0.044	0.028	0.019	0.011	0.007
4	0.181	0.289	0.243	0.142	0.072	0.039	0.021	0.010	0.003
5	0.066	0.159	0.237	0.238	0.139	0.081	0.049	0.024	0.007
6	0.020	0.057	0.111	0.169	0.207	0.175	0.142	0.092	0.027
7	0.003	0.015	0.048	0.117	0.216	0.259	0.214	0.113	0.016
8	0.014	0.030	0.050	0.078	0.106	0.131	0.167	0.238	0.186
9	0.277	0.202	0.147	0.110	0.076	0.059	0.052	0.042	0.035

28 **Table10. NMA results of the UA.** (1 Conventional drugs; 2 Acupuncture; 3 Acupuncture +

29 conventional drugs; 4 Acupotomy; 5 Acupotomy + conventional drugs; 6 Blood-letting; 7 Blood-
 30 letting+ conventional drugs; 8 Warm acupuncture + conventional drugs; 9 Fire acupuncture; 10 Warm
 31 acupuncture; and 11 Electroacupuncture + conventional drugs.)

	X1	X2	X3	X4	X5	X6	X7	X8	X9	X10	X11	
1	1	-64.81 (-118.68,- 13.75)	-77.85 (-151.89,- 15.3)	-28.32(-12 0.69,61.76)	-78.35 (-166.56,1 0.29)	-41.78(-93 .52,10.53)	-35.28 (-123.38,5 4.04)	-11.25 (-135.56,1 13.13)	-36.92 (-126.18,5 2.29)	-47.62 (-179.38,8 3.65)	-10.92 (-135.81,1 14.09)	
2	64.81 (13.75,11 8.68)	2	-13.07 (-102.61,6 8.07)	36.34(-68. 69,141.91)	-13.56 (-115.37,9 0.46)	23.05(-49. 16,98.41)	29.44 (-71.9,134 .22)	53.47 (-80,33,19 0.92)	27.79 (-74,1,132 .92)	17.4 (-123,52,1 59.64)	53.93 (-79,79,19 0.23)	
3	77.85 (15.3,151. 89)	13.07 (-68.07,10 2.61)	3	49.66(-59. 55,167.63)	-0.53 (-106.33,1 17.47)	36.13(-43. 96,127.61)	42.35 (-63,4,160 .26)	66.32 (-69,21,21 4.35)	41 (-65,7,159 .09)	30.52 (-112,52,1 83.29)	66.85 (-70,13,21 4.21)	
4	28.32 (-61.76,12 0.69)	-36.34 (-141.91,6 8.69)	-49.66 (-167.63,5 9.55)	4	-50.16 (-175.98,7 8.26)	-13.34(-11 7.02,92.87)	-7.08 (-132.22,1 22.7)	17.08 (-135.82,1 72.44)	-8.65 (-134,96,1 20.6)	-19.13 (-178.91,1 41.68)	17.49 (-135,87,1 73.73)	
5	78.35 (6.56) 41.78	13.56 (5.37) -23.05	0.53 (06.33) -36.13	50.16(-78. 13,34(-92. -36,74(-13))	5	26.71(-66. 13.08) 6.33	13.08 (8.39) 30.44	67.15 (85.81,22 0.04)	41.57(-83. 81,167.11)	30.97 (-127,3,18 9.5)	67.7 (-86,02,21 9.82)	
6	-10.53,93 .52)	(-98.41,49 .16)	(-127.61,4 3.96)	87,117.02)	9.55,66.16)	6	(-96.53,11 0.02)	(-104,53,1 65.14)	(-98,76,10 8.43)	(-147,76,1 35.95)	(-104,82,1 66.26)	
7	35.28 (-54.04,12 3.38)	-29.44 (-134.22,7 1.9)	-42.35 (-160.26,6 3.4)	7.08(-122. 7,132.22)	-43.08(-16 8.39,81.85)	-6.33 (-110.02,9 6.53)	7	23.83 (-128.63,1 76.84)	-1.67 (-127,8,12 3.81)	-12.23 (-170,74,1 46.24)	24.46 (-129,42,1 77.06)	
8	11.25 (-113.13,1 35.56)	-53.47 (-190.92,8 0.33)	-66.32 (-214.35,6 9.21)	-17.08(-17 2.44,135.8 2)	-67.15(-22 0.04,85.81)	-30.44 (-165.14,1 04.53)	-23.83 (-176.84,1 28.63)	8	25.57 (-127,64,1 78.18)	-25.57 (-178,18,1 27.64)	-36.09 (-217,25,1 45.37)	0.41 (-176,42,1 76.39)
9	36.92 (-52.29,12 6.18)	-27.79 (-132.92,7 4.1)	-41 (-159.09,6 5.7)	8.65(-120. 6,134.96)	-41.57(-16 7.11,83.81)	-4.75 (-108.43,9 8.76)	1.67 (-123.81,1 27.8)	25.57 (-127,64,1 78.18)	9	-10.78 (-169,87,1 48.53)	25.91 (-128,179. 43)	
10	47.62 (-83.65,17 9.38)	-17.4 (-159.64,1 23.52)	-30.52 (-183.29,1 12.52)	19.13(-14 1.68,178.9 1)	-30.97(-18 9,5,127.3)	5.7 (-135.95,1 47.76)	12.23 (-146,24,1 70.74)	36.09 (-145,37,2 17.25)	10.78 (-148,53,1 69.87)	10	36.36 (-144,37,2 17.5)	
11	10.92 (-114.09,1 35.81)	-53.93 (-190.23,7 9.79)	-66.85 (-214.21,7 0.13)	-17.49(-17 3.73,135.8 7)	-67.7(-219 .82,86.02)	-30.92 (-166.26,1 04.82)	-24.46 (-177.06,1 29.42)	-0.41 (-176,39,1 76.42)	-25.91 (-179,43,1 28)	-36.36 (-217,5,14 4.37)	11	

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.21.24314132>; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

32 **Table11. Probability ranking results of the UA.** (1 Conventional drugs; 2 Acupuncture; 3 Ac
 33 acupuncture + conventional drugs; 4 Acupotomy; 5 Acupotomy + conventional drugs; 6 Blood-letting; 7
 34 Blood-letting+ conventional drugs; 8 Warm acupuncture + conventional drugs; 9 Fire acupuncture; 10
 35 Warm acupuncture; and 11 Electroacupuncture + conventional drugs.)

	V1	V2	V3	V4	V5	V6	V7	V8	V9	V10	V11
1	0.000	0.000	0.000	0.000	0.002	0.014	0.064	0.182	0.319	0.301	0.118
2	0.081	0.156	0.193	0.185	0.152	0.106	0.068	0.036	0.015	0.005	0.001
3	0.215	0.220	0.177	0.133	0.099	0.069	0.045	0.025	0.011	0.005	0.002
4	0.041	0.055	0.067	0.079	0.091	0.106	0.119	0.120	0.110	0.112	0.100
5	0.273	0.183	0.135	0.108	0.086	0.071	0.054	0.038	0.025	0.017	0.010
6	0.015	0.043	0.082	0.126	0.164	0.181	0.165	0.119	0.065	0.030	0.010
7	0.049	0.067	0.080	0.092	0.104	0.116	0.121	0.114	0.097	0.088	0.071
8	0.051	0.049	0.050	0.053	0.062	0.071	0.083	0.092	0.098	0.138	0.253
9	0.054	0.072	0.083	0.094	0.105	0.117	0.120	0.111	0.093	0.084	0.068
10	0.169	0.104	0.084	0.077	0.075	0.078	0.078	0.074	0.070	0.083	0.109
11	0.052	0.050	0.050	0.053	0.060	0.070	0.083	0.089	0.098	0.137	0.258

36 **Table12. NMA results of the CRP.** (1 Conventional drugs; 2 Acupuncture; 3 Acupuncture +
 37 conventional drugs; 4 Blood-letting; 5 Blood-letting + conventional drugs; 6 Electroacupuncture +
 38 conventional drugs; 7 Warm acupuncture + conventional drugs.)

	X1	X2	X3	X4	X5	X6	X7
--	----	----	----	----	----	----	----

1	1	8.88	-4.42	-6.37	-10.94	-2.33	-15.35
		(-17.72,35.36)	(-21.2,12.02)	(-29.31,16.66)	(-29.21,3.78)	(-24.65,19.97)	(-37.69,7.15)
2	-8.88	2	-13.29	-15.27	-20.09	-11.22	-24.24
	(-35.36,17.72)		(-44.57,17.77)	(-50.11,19.65)	(-52.8,9.62)	(-45.57,23.32)	(-58.56,10.39)
3	4.42	13.29	3	-1.98	-6.4	2.07	-10.92
	(-12.02,21.2)	(-17.77,44.57)		(-30.02,26.53)	(-31.69,15.1)	(-25.65,30.21)	(-38.71,17.24)
4	6.37	15.27	1.98	4	-4.46	4.07	-8.95
	(-16.66,29.31)	(-19.65,50.11)	(-26.53,30.02)		(-34.74,21.66)	(-27.98,35.87)	(-41.02,23.08)
5	10.94	20.09	6.4	4.46	5	8.31	-4.64
	(-3.78,29.21)	(-9.62,52.8)	(-15.1,31.69)	(-21.66,34.74)		(-17.25,38.17)	(-30.19,25.31)
6	2.33	11.22	-2.07	-4.07	-8.31	6	-13.01
	(-19.97,24.65)	(-23.32,45.57)	(-30.21,25.65)	(-35.87,27.98)	(-38.17,17.25)		(-44.48,18.76)
7	15.35	24.24	10.92	8.95	4.64	13.01	7
	(-7.15,37.69)	(-10.39,58.56)	(-17.24,38.71)	(-23.08,41.02)	(-25.31,30.19)	(-18.76,44.48)	

39 **Table13. Probability ranking results of the CRP.** (1 Conventional drugs; 2 Acupuncture; 3

40 Acupuncture + conventional drugs; 4 Blood-letting; 5 Blood-letting + conventional drugs; 6

41 Electroacupuncture + conventional drugs; 7 Warm acupuncture + conventional drugs.)

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.21.20116212>; this version posted September 21, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

	V1	V2	V3	V4	V5	V6	V7
1	0.000	0.005	0.037	0.151	0.337	0.394	0.076
2	0.019	0.033	0.047	0.060	0.072	0.119	0.651
3	0.045	0.113	0.215	0.267	0.176	0.128	0.056
4	0.112	0.189	0.229	0.173	0.118	0.111	0.068
5	0.216	0.379	0.226	0.102	0.044	0.023	0.009
6	0.053	0.085	0.137	0.186	0.218	0.198	0.123
7	0.555	0.196	0.109	0.061	0.035	0.028	0.016

42 **Table14. NMA results of the ESR.**(1 Conventional drugs; 2 Acupuncture; 3 Acupuncture +

43 conventional drugs; 4 Blood-letting; 5 Blood-letting + conventional drugs; 6 Warm acupuncture +

44 conventional drugs.)

	X1	X2	X3	X4	X5	X6
1	1	-6.04	-6.13	-7.84	-9.6	-4.55(-19.14,10.02)
		(-17.07,5.18)	(-11.66,-0.55)	(-14.11,1.37)	(-17.92,-3.06)	
2	6.04	2	-0.08	-1.7	-3.61	1.43(-16.86,19.66)
	(-5.18,17.07)		(-12.63,12.24)	(-14.12,12.9)	(-17.86,8.95)	
3	6.13	0.08	3	-1.73	-3.46	1.59(-13.85,17.04)
	(0.55,11.66)	(-12.24,12.63)		(-9.78,9.32)	(-13.71,4.82)	
4	7.84	1.7	1.73	4	-1.78	3.09
	(-1.37,14.11)	(-12.9,14.12)	(-9.32,9.78)		(-15,6.84)	(-14.02,18.61)
5	9.6	3.61	3.46	1.78	5	5.14
	(3.06,17.92)	(-8.95,17.86)	(-4.82,13.71)	(-6.84,15)		(-10.63,21.88)
6	4.55	-1.43	-1.59	-3.09	-5.14	6
	(-10.02,19.14)	(-19.66,16.86)	(-17.04,13.85)	(-18.61,14.02)	(-21.88,10.63)	

45 **Table15. Probability ranking results of the ESR.** (1 Conventional drugs; 2 Acupuncture; 3

46 Acupuncture + conventional drugs; 4 Blood-letting ; 5 Blood-letting + conventional drugs; 6 Warm

47 acupuncture + conventional drugs.)

	V1	V2	V3	V4	V5	V6
1	0.000	0.001	0.007	0.051	0.310	0.631
2	0.163	0.155	0.167	0.220	0.203	0.091
3	0.042	0.142	0.300	0.343	0.163	0.010
4	0.179	0.296	0.257	0.166	0.078	0.023
5	0.434	0.294	0.161	0.080	0.028	0.004

48 **Table16. Adverse reaction of the included studies.**

STUDY	REPORTED ADVERSE REACTIONS
CHENGZHENFENG2019	Conventional drugs: 11 cases (Nausea, vomiting, drowsiness, headache, etc.) Acupuncture: 1 cases (Mild erythema and edema at the needle puncture site, alleviated with hot compresses).
CHENZIQING2020	Conventional drugs: 4 cases (Minor gastrointestinal symptoms.) Warm acupuncture therapy + conventional drugs: 11 cases (Localized skin bruising following acupuncture, which resolves spontaneously.)
GAOLI2019	Conventional drugs: 7 cases (Gastrointestinal reactions, hepatic damage, renal impairment, and allergic reactions). Electroacupuncture + conventional drugs: 8 例 (Gastrointestinal reactions, hepatic damage, renal impairment, allergic reactions, localized hematomas, and needle sickness).
LIUXIN2000	Conventional drugs: 6 cases (Gastrointestinal reactions and alterations in hematocrit levels). Warm acupuncture therapy : cases.
QINZHIZHOU2016	Conventional drugs: 7 cases (Decreased appetite, diarrhea, and mild hepatic impairment). Blood-letting therapy: 0 cases.
QIUFANGHUI2018	Conventional drugs: 4 cases (Gastrointestinal symptoms). Blood-letting therapy: 1 case (Pruritus and erythema of the skin.).
SUNJUNGANG2016	Conventional drugs: 8 cases (Not described in studies). Blood-letting therapy: 1 case (Not described in studies).
WUBAIQIANG2016	Conventional drugs: 4 cases (Mild nausea and vomiting, along with dizziness, weakness, and other related symptoms). Electroacupuncture + conventional drugs: 3 cases (Mild nausea and vomiting, accompanied by dizziness, weakness, and other related symptoms).
WURONG2020	Conventional drugs: 8 cases (Bloating, abdominal pain, nausea, vomiting, and other associated symptoms). Acupuncture: 1 cases (Hematoma at the site of the needle insertion).
YANGLIFAN2023	Conventional drugs: 6 cases (Severe diarrhea, nausea and vomiting, reduced food intake, and dizziness). Acupuncture+Conventional drugs:3 cases (Severe diarrhea, nausea with vomiting, and decreased dietary intake).

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.21.24314132>; this version posted September 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

49 1 Conventional drugs; 2 Acupuncture; 3 Acupuncture + conventional drugs; 4 Acupotomy; 5 Acupotomy + conventional drugs; 6 Blood-letting therapy; 7 Blood-letting therapy + conventional drugs; 8 Electroacupuncture + conventional drugs; 9 Warm acupuncture therapy + conventional drugs; 10 Fire acupuncture; 11 Warm acupuncture therapy.

53